This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Molecular Partners Ag. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Matteo Bianchi: Innovator in Multi-Specific T-Cell Engagers
Introduction
Matteo Bianchi is a prominent inventor based in Schlieren, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of multi-specific proteins for therapeutic applications.
Latest Patents
Matteo Bianchi holds a patent for "DARPin based multi-specific t-cell engagers." This invention relates to recombinant multi-specific proteins that include binding agents with specificity for various targets, such as CD3, CD33, CD123, and CD70. The patent also encompasses nucleic acids encoding these multi-specific proteins, pharmaceutical compositions containing them, and their use in treating or diagnosing diseases, including acute myeloid leukaemia (AML) in mammals, including humans.
Career Highlights
Matteo Bianchi is associated with Molecular Partners AG, a company known for its innovative approaches in the field of protein engineering. His work has been instrumental in advancing therapeutic strategies that leverage the immune system to combat cancer.
Collaborations
Matteo collaborates with talented professionals in his field, including Nina Reschke and Sebastian Grimm. Their combined expertise contributes to the ongoing research and development efforts at Molecular Partners AG.
Conclusion
Matteo Bianchi's innovative work in the realm of multi-specific t-cell engagers showcases his commitment to advancing cancer treatment. His contributions are paving the way for new therapeutic options that could significantly impact patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile